These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10606763)

  • 21. Identification of a target site in plasminogen activator inhibitor-1 that allows neutralization of its inhibitor properties concomitant with an allosteric up-regulation of its antiadhesive properties.
    Ngo TH; Hoylaerts MF; Knockaert I; Brouwers E; Declerck PJ
    J Biol Chem; 2001 Jul; 276(28):26243-8. PubMed ID: 11342530
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural determinants in the stability of the serpin/proteinase complex.
    De Taeye B; Verbeke K; Compernolle G; Biesemans W; Gils A; Declerck PJ
    Biochem Biophys Res Commun; 2003 Aug; 307(3):529-34. PubMed ID: 12893254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutational analysis of plasminogen activator inhibitor-1.
    Wind T; Jensen JK; Dupont DM; Kulig P; Andreasen PA
    Eur J Biochem; 2003 Apr; 270(8):1680-8. PubMed ID: 12694181
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interfering with the inhibitory mechanism of serpins: crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide.
    Xue Y; Björquist P; Inghardt T; Linschoten M; Musil D; Sjölin L; Deinum J
    Structure; 1998 May; 6(5):627-36. PubMed ID: 9634700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.
    Li SH; Gorlatova NV; Lawrence DA; Schwartz BS
    J Biol Chem; 2008 Jun; 283(26):18147-57. PubMed ID: 18436534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of serpin reaction through stabilization of transient intermediate by ligands bound to alpha-helix F.
    Komissarov AA; Zhou A; Declerck PJ
    J Biol Chem; 2007 Sep; 282(36):26306-15. PubMed ID: 17613529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.
    Sharp AM; Stein PE; Pannu NS; Carrell RW; Berkenpas MB; Ginsburg D; Lawrence DA; Read RJ
    Structure; 1999 Feb; 7(2):111-8. PubMed ID: 10368279
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immobilization of the distal hinge in the labile serpin plasminogen activator inhibitor 1: identification of a transition state with distinct conformational and functional properties.
    De Taeye B; Compernolle G; Dewilde M; Biesemans W; Declerck PJ
    J Biol Chem; 2003 Jun; 278(26):23899-905. PubMed ID: 12686544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms.
    Sancho E; Declerck PJ; Price NC; Kelly SM; Booth NA
    Biochemistry; 1995 Jan; 34(3):1064-9. PubMed ID: 7827021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The vitronectin binding area of plasminogen activator inhibitor-1, mapped by mutagenesis and protection against an inactivating organochemical ligand.
    Jensen JK; Wind T; Andreasen PA
    FEBS Lett; 2002 Jun; 521(1-3):91-4. PubMed ID: 12067733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of a functional epitope in plasminogen activator inhibitor-1, not localized in the reactive center loop.
    Debrock S; Declerck PJ
    Thromb Haemost; 1998 Mar; 79(3):597-601. PubMed ID: 9531048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type-1 plasminogen-activator inhibitor -- conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility.
    Egelund R; Schousboe SL; Sottrup-Jensen L; Rodenburg KW; Andreasen PA
    Eur J Biochem; 1997 Sep; 248(3):775-85. PubMed ID: 9342229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of the hinge region between alpha-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies.
    Bijnens AP; Gils A; Knockaert I; Stassen JM; Declerck PJ
    J Biol Chem; 2000 Mar; 275(9):6375-80. PubMed ID: 10692438
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distinct encounter complexes of PAI-1 with plasminogen activators and vitronectin revealed by changes in the conformation and dynamics of the reactive center loop.
    Qureshi T; Goswami S; McClintock CS; Ramsey MT; Peterson CB
    Protein Sci; 2016 Feb; 25(2):499-510. PubMed ID: 26548921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR; van den Berg BM; Moestrup SK; Pannekoek H; van Zonneveld AJ
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of stabilizing versus destabilizing interactions on plasminogen activator inhibitor-1.
    Vleugels N; Leys J; Knockaert I; Declerck PJ
    J Pharm Belg; 2000; 55(2):57-8. PubMed ID: 10842928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex to the endocytosis receptors alpha2-macroglobulin receptor/low-density lipoprotein receptor-related protein and very-low-density lipoprotein receptor involves basic residues in the inhibitor.
    Rodenburg KW; Kjoller L; Petersen HH; Andreasen PA
    Biochem J; 1998 Jan; 329 ( Pt 1)(Pt 1):55-63. PubMed ID: 9405275
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Engineering of conformations of plasminogen activator inhibitor-1. A crucial role of beta-strand 5A residues in the transition of active form to latent and substrate forms.
    Kirkegaard T; Jensen S; Schousboe SL; Petersen HH; Egelund R; Andreasen PA; Rodenburg KW
    Eur J Biochem; 1999 Jul; 263(2):577-86. PubMed ID: 10406969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibitory mechanism of serpins: loop insertion forces acylation of plasminogen activator by plasminogen activator inhibitor-1.
    Kvassman JO; Verhamme I; Shore JD
    Biochemistry; 1998 Nov; 37(44):15491-502. PubMed ID: 9799512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kinetically controlled folding of the serpin plasminogen activator inhibitor 1.
    Wang Z; Mottonen J; Goldsmith EJ
    Biochemistry; 1996 Dec; 35(51):16443-8. PubMed ID: 8987976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.